Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Radiotherapy 5Biopsy 4Radiation 3Cytarabine 3Cyclophosphamide 3venetoclax 2Vincristine 2Standard of Care 2Spinal Puncture 2Practice Guidelines as Topic 2High-Energy Shock Waves 2Daunorubicin 2Azacitidine 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1sulforaphane 1sacituzumab govitecan 1revumenib 1prednylidene 1pertuzumab 1pembrolizumab 1pegaspargase 1nelarabine 1merphos 1liposomal doxorubicin 1lenvatinib 1gilteritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NETWORK × gilteritinib × Clear all
NCT07425808 2026-02-23

FIT-AML

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Not yet recruiting
230 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡